All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Zanubrutinib versus acalabrutinib in R/R CLL: an indirect comparison
Bookmark this article
On February 29, 2024, it was announced that zanubrutinib demonstrated improved progression-free survival and complete response versus acalabrutinib in a recent matching adjusted indirect comparison (MAIC) analysis. The MAIC analysis was based on the efficacy outcomes of zanubrutinib versus acalabrutinib from the phase III ALPINE and ASCEND trials in patients with relapsed or refractory chronic lymphocytic leukemia.
The individual patient-level data from ALPINE was matched against the aggregate data from the ASCEND trial. Key results from the indirect comparison were as follows:
-
Improved investigator-assessed progression-free survival for zanubrutinib versus acalabrutinib in both unadjusted (hazard ratio [HR], 0.77 ;95% confidence interval [CI], 0.55–1.07), and base case adjusted (HR, 0.68; 95% CI, 0.46–0.99) populations
-
Improved complete response for zanubrutinib versus acalabrutinib in the unadjusted (odds ratio [OR], 2.88; 95%CI, 1.18–7.02]) and base case adjusted populations (OR, 2.90; 95%CI, 1.13–7.43)
-
A trend towards improved overall survival for zanubrutinib versus acalabrutinib
Overall, this comprehensive MAIC analysis demonstrated a PFS and CR advantage, and improved OS for zanubrutinib compared with acalabrutinib.
- Business Wire. BeiGene announces new efficacy analysis comparing BRUKINSA® vs acalabrutinib in relapsed or refractory chronic lymphocytic leukemia. https://www.businesswire.com/news/home/20240229874068/en/BeiGene-Announces-New-Efficacy-Analysis-Comparing-BRUKINSA%C2%AE-vs-Acalabrutinib-in-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia. Published Feb 29, 2024. Accessed Mar 1, 2024.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox